What is Scribe Therapeutics?
Scribe Therapeutics operates as a high-growth biotechnology firm dedicated to revolutionizing the landscape of genetic medicine. Through its innovative CRISPR-based molecular engineering, the company targets the root causes of prevalent health conditions, including complex cardiometabolic diseases. By moving beyond traditional symptomatic treatment, Scribe aims to redefine health outcomes, ensuring that genetic predispositions no longer dictate long-term patient wellness. The firm maintains a robust collaborative model, partnering with leading pharmaceutical entities to accelerate the development of its therapeutic pipeline and expand its reach across diverse medical domains.
The company's growth trajectory is marked by a clear progression from its initial Series A round in October 2020 to its substantial Series B expansion in March 2021. This capital infusion has enabled the firm to scale its research infrastructure and deepen its commitment to accessible, preventative genetic interventions, positioning it as a critical player in the next generation of life sciences innovation.
How much funding has Scribe Therapeutics raised?
Scribe Therapeutics has raised a total of $120M across 2 funding rounds:
Series A
$20M
Series B
$100M
Series A (2020): $20M with participation from Andreessen Horowitz
Series B (2021): $100M led by Avoro Capital Advisors LLC, OrbiMed Advisors LLC, and Andreessen Horowitz
Key Investors in Scribe Therapeutics
OrbiMed Advisors LLC
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation at various stages of development.
Andreessen Horowitz
A prominent venture capital firm that invests in transformative technology companies, providing strategic guidance and capital to support long-term growth in the biotech and software sectors.
Avoro Capital Advisors LLC
An investment firm specializing in the healthcare and life sciences sectors, providing strategic backing to companies developing novel therapeutic solutions.
What's next for Scribe Therapeutics?
With the successful closure of its latest funding cycle, Scribe Therapeutics is well-positioned to transition from foundational research into advanced clinical development. The strategic deployment of this capital will likely focus on expanding the company's molecular engineering capabilities and strengthening its pharmaceutical partnerships to facilitate broader therapeutic access. As the firm continues to refine its CRISPR-based platforms, the focus will shift toward navigating regulatory milestones and scaling its manufacturing processes to meet the demands of a global market. Investors remain optimistic that Scribe's preventative approach will yield significant long-term value, potentially disrupting the standard of care for chronic and genetic-linked diseases.
See full Scribe Therapeutics company page
